Roquefort Therapeutics signs term sheet for $10 million sale of subsidiary
LONDON: Roquefort Therapeutics (LSE:ROQ), a publicly traded biotech company, announced it has signed a term sheet for the sale of its wholly-owned subsidiary, Lyramid Pty Ltd, to Pleiades Pharma Limited. The proposed deal values Lyramid at a minimum of $10…